ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Gynecomastia: A Multicenter Study
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 115059" data-attributes="member: 3"><p>Highest prevalence of gynecomastia was observed between 21 and 30 years (n = 74; 31.2%). The most common presenting complaints were aesthetic concerns (62.8%) and breast pain (51.2%). 25.3% of the subjects had a history of pubertal gynecomastia. 56.5% had bilateral gynecomastia. 39.9% were overweight and 22.8% were obese. The etiology could not be identified in 45.1% of the cases; the most frequent identified causes were anabolic steroids consumption (13.9%), hypogonadism (11.1%), and use of pharmaceutical drugs (7.8%). Patients with bilateral gynecomastia had a longer history of disease, higher BMI, and lower testosterone levels.</p><p></p><p>The hormones involved in breast tissue physiology may be stimulatory (as estradiol and progesterone) or inhibitory (as testosterone), acting directly through their specific receptors at this level [6, 7]. Receptors for insulin-like growth factor 1 (IGF-1), IGF-2 [8], luteinizing hormone, and human chorionic gonadotropin have also been detected in breast tissue [7, 8]. <strong>Estrogens and progesterone apparently require the presence of growth hormone and IGF-1 to exert their stimulatory action on the breast </strong>[9]. Hyperprolactinemia may indirectly cause gynecomastia by suppressing gonadotropin-releasing hormone (GnRH) release, resulting in central hypogonadism, although prolactin receptors have also been detected in benign and malignant breast tissue. At breast level, prolactin might modulate progesterone and androgen receptors expression (increasing the former and reducing the latter) [10]. Furthermore, prolactin stimulates epithelial cell proliferation only in the presence of estrogen and enhances lobuloalveolar differentiation only with concomitant progesterone [7].</p><p></p><p><strong>Gynecomastia may result from an excess of estrogens (obesity, tumors, and exogenous sources) [11] with androgen deficiency (hypogonadism), hormone resistance [12], or altered ratio of estrogens to androgens (refeeding, liver disease, and renal failure)</strong> [13].</p><p></p><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996435/" target="_blank">Full paper</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 115059, member: 3"] Highest prevalence of gynecomastia was observed between 21 and 30 years (n = 74; 31.2%). The most common presenting complaints were aesthetic concerns (62.8%) and breast pain (51.2%). 25.3% of the subjects had a history of pubertal gynecomastia. 56.5% had bilateral gynecomastia. 39.9% were overweight and 22.8% were obese. The etiology could not be identified in 45.1% of the cases; the most frequent identified causes were anabolic steroids consumption (13.9%), hypogonadism (11.1%), and use of pharmaceutical drugs (7.8%). Patients with bilateral gynecomastia had a longer history of disease, higher BMI, and lower testosterone levels. The hormones involved in breast tissue physiology may be stimulatory (as estradiol and progesterone) or inhibitory (as testosterone), acting directly through their specific receptors at this level [6, 7]. Receptors for insulin-like growth factor 1 (IGF-1), IGF-2 [8], luteinizing hormone, and human chorionic gonadotropin have also been detected in breast tissue [7, 8]. [B]Estrogens and progesterone apparently require the presence of growth hormone and IGF-1 to exert their stimulatory action on the breast [/B][9]. Hyperprolactinemia may indirectly cause gynecomastia by suppressing gonadotropin-releasing hormone (GnRH) release, resulting in central hypogonadism, although prolactin receptors have also been detected in benign and malignant breast tissue. At breast level, prolactin might modulate progesterone and androgen receptors expression (increasing the former and reducing the latter) [10]. Furthermore, prolactin stimulates epithelial cell proliferation only in the presence of estrogen and enhances lobuloalveolar differentiation only with concomitant progesterone [7]. [B]Gynecomastia may result from an excess of estrogens (obesity, tumors, and exogenous sources) [11] with androgen deficiency (hypogonadism), hormone resistance [12], or altered ratio of estrogens to androgens (refeeding, liver disease, and renal failure)[/B] [13]. [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996435/']Full paper[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Gynecomastia: A Multicenter Study
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top